Every 8-K that Reliance Global Group, Inc. Series A Warrants (EZRAW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EZRAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EZRAW filings page.
Reliance Global Group, Inc. has regained compliance with Nasdaq’s continued listing rules after its stock met the exchange’s minimum bid price requirement. Nasdaq confirmed that the company’s common stock closed at or above $1.00 per share for 10 consecutive business days from May 18, 2026 through June 1, 2026, resolving a prior deficiency notice issued in December 2025. The company remains listed on the Nasdaq Capital Market and highlighted ongoing efforts to expand its Insurtech platforms and EZRA International Group while pursuing long-term shareholder value.
Reliance Global Group, Inc. approved and implemented a 1-for-40 reverse stock split of its common stock to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The amendment to the articles of incorporation is scheduled to become effective at 5:00 p.m. Eastern on May 15, 2026.
Every 40 existing shares will convert into one share, reducing the amount of common stock outstanding from approximately 22,230,563 shares to 555,764 shares, while authorized common shares will be set at 50 million and par value stays at $0.086 per share. Trading on a split-adjusted basis on the Nasdaq Capital Market under the symbol EZRA and new CUSIP 75946W504 is expected to begin on May 18, 2026, with each shareholder’s ownership percentage remaining the same.
Reliance Global Group, Inc. reported results from its 2026 Annual Meeting of Stockholders, held via live webcast. As of March 5, 2026, there were 21,253,013 common shares outstanding and entitled to vote, and 9,591,634 shares were represented, about 45.13% of those eligible.
Stockholders elected five directors to serve until the 2027 annual meeting and ratified Urish Popeck & Co., LLC as independent auditor for the year ending December 31, 2026. Each director nominee received over 3.27 million votes for, with substantial broker non-votes.
Investors also approved an amendment to the 2025 Equity Incentive Plan, increasing shares available for issuance by 14,000,000, from 2,000,000 to 16,000,000. In a separate proposal, stockholders approved issuing common shares in excess of the Nasdaq Exchange Cap under a Common Stock Purchase Agreement dated August 26, 2025, as amended.
Reliance Global Group formed LifeSci Global Group LLC, a majority-owned healthcare investment vehicle, and funded it using a Promissory Note of up to $2,000,000 from its subsidiary EZRA International Group.
LifeSci Global agreed to purchase up to 421,053 Innervate Radiopharmaceuticals units at $4.75 per unit, totaling about $2.0 million, with $500,000 funded at closing. The deal includes priority distributions and up to 210,526 warrants and was approved by independent directors as a related-party transaction, with committee reshuffling to ensure board independence.
Reliance Global Group, Inc. entered into two settlement agreements to resolve disputes tied to prior stock purchase transactions. The company will pay a cash settlement of $90,560 under the Rubin Settlement Agreement and $40,350 under the Kreindler Settlement Agreement, after which all related obligations are fully released.
The company also amended its Common Stock Purchase Agreement with White Lion Capital to extend the investment commitment period through the earlier of reaching the commitment amount or December 31, 2028, and increased the commitment amount to $50,000,000. In addition, Reliance Global Group adopted amended and restated bylaws to give the board flexibility in setting annual meeting dates and filed Articles of Restatement that restate its articles of incorporation in full.
Reliance Global Group, Inc. reported that its Board Compensation Committee approved a one-time cash bonus for Chief Financial Officer Joel Markovits. On March 2, 2026, the Committee granted Mr. Markovits a $50,000 gross cash award, which will be paid subject to standard tax withholding and authorized deductions.
Reliance Global Group has completed the initial closing of its strategic acquisition of Enquantum Ltd., a post-quantum cryptography company. At closing, Reliance acquired an equity stake representing approximately 8% of Enquantum’s fully diluted share capital through conversion of a previously issued $166,000 secured bridge note and an additional cash investment.
The share purchase agreement is structured as milestone-based tranches that are designed to increase Reliance’s ownership to 51% on a fully diluted basis, subject to specified operational and commercialization milestones and other conditions. A new amendment gives Reliance the right, at its sole discretion, to accelerate funding of one or more tranches even if the related milestones have not yet been met.
Reliance also agreed it may later issue up to $125,000 of its common stock as “Top-Up Shares” to raise its Enquantum stake from 48% to 51% on a fully diluted basis. Enquantum shares issued to Reliance were placed offshore under Regulation S and/or Section 4(a)(2), and any Top-Up Shares are expected to rely on Section 4(a)(2) and/or Regulation D. Reliance’s CEO, Ezra Beyman, has joined Enquantum’s board under the agreement’s governance terms as Reliance seeks to build Enquantum into a core post-quantum cybersecurity platform.
Reliance Global Group, Inc. entered into a definitive Share Purchase Agreement to acquire, over time, a 51% fully diluted controlling interest in post-quantum cybersecurity company Enquantum Ltd. for an aggregate purchase price of $2,125,000, paid in milestone-based tranches over about 10 months.
At the initial closing, Reliance expects to obtain an 8% fully diluted stake, including conversion of a previously issued $166,000 bridge note and a cash-funded share issuance. Subsequent monthly tranches are generally structured to increase ownership by 4% per month up to 48%, followed by a final “control top-up” from 48% to 51%.
As part of the control top-up, Reliance has agreed to issue Enquantum common stock valued at $125,000, based on the last reported Nasdaq sale price before the relevant closing, and does not expect to receive cash proceeds from these shares. Reliance plans to hold board control upon achieving specified milestones and to develop Enquantum within its EZRA International Group and Scale51 operating strategy.
Reliance Global Group, Inc. filed Amendment No. 3 to its prospectus supplement, allowing ongoing at-the-market sales of common stock with an aggregate offering price of up to $1,764,443 under its existing agreement with H.C. Wainwright & Co., LLC as manager.
The amendment updates and supplements the company’s Form S-3 shelf registration and earlier prospectus supplements. Reliance Global Group has already offered and sold $2,343,660 of common stock under Form S-3 General Instruction I.B.6 during the 12-month period ending on the amendment date. A legal opinion from Zarif Law Group P.C. on the validity of the shares is included as an exhibit.